CVRx (NASDAQ:CVRX) Major Shareholder Sells $534,309.72 in Stock

CVRx, Inc. (NASDAQ:CVRX) major shareholder & Johnson Johnson sold 52,332 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $10.21, for a total value of $534,309.72. Following the completion of the transaction, the insider directly owned 4,051,098 shares in the company, valued at approximately $41,361,710.58. This trade represents a 1.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

& Johnson Johnson also recently made the following trade(s):

• On Friday, November 7th, & Johnson Johnson sold 200 shares of CVRx stock. The stock was sold at an average price of $10.00, for a total value of $2,000.00.

CVRx Price Performance

CVRX opened at $9.52 on Thursday. The company has a market capitalization of $248.97 million, a price-to-earnings ratio of -4.53 and a beta of 1.28. The company has a current ratio of 11.99, a quick ratio of 10.78 and a debt-to-equity ratio of 0.85. CVRx, Inc. has a 12-month low of $4.30 and a 12-month high of $18.55. The business’s fifty day simple moving average is $8.85 and its 200-day simple moving average is $7.63.

CVRx (NASDAQ:CVRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.01. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. The company had revenue of $14.69 million during the quarter, compared to analyst estimates of $14.16 million. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts anticipate that CVRx, Inc. will post -1.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CVRX. Canaccord Genuity Group lifted their price objective on shares of CVRx from $9.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CVRx in a report on Thursday, October 30th. Finally, Cantor Fitzgerald boosted their price target on CVRx from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.17.

Institutional Investors Weigh In On CVRx

A number of large investors have recently modified their holdings of CVRX. Cresset Asset Management LLC increased its holdings in shares of CVRx by 34.1% during the third quarter. Cresset Asset Management LLC now owns 71,802 shares of the company’s stock valued at $579,000 after acquiring an additional 18,260 shares in the last quarter. Vanguard Group Inc. boosted its stake in CVRx by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,090,226 shares of the company’s stock worth $8,798,000 after purchasing an additional 12,948 shares in the last quarter. Perkins Capital Management Inc. grew its position in CVRx by 20.8% during the 3rd quarter. Perkins Capital Management Inc. now owns 19,750 shares of the company’s stock worth $159,000 after purchasing an additional 3,400 shares during the last quarter. Stoneridge Investment Partners LLC grew its position in CVRx by 7.9% during the 3rd quarter. Stoneridge Investment Partners LLC now owns 20,126 shares of the company’s stock worth $162,000 after purchasing an additional 1,471 shares during the last quarter. Finally, Inscription Capital LLC acquired a new position in CVRx during the 3rd quarter valued at approximately $139,000. Hedge funds and other institutional investors own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.